(HALO) Halozyme Therapeutics, Inc. Business Model Canvas Research

Halozyme Therapeutics, Inc. works with Alexion Pharma Holding and Horizon Therapeutics to adapt complex biologics for subcutaneous use. The ENHANZE platform can cut treatment time from hours to minutes, which helps rare-disease and specialty-medicine drugs reach patients faster and with less clinic burden.

• Supports subcutaneous biologic delivery
• Expands rare-disease reach
• Improves patient convenience

Halozyme’s HIV research partners include NIAID, CAPRISA, and ViiV Healthcare Limited, linking its ENHANZE platform to small- and large-molecule HIV targets for treatment and prevention. This widens its R&D reach beyond pharma licensing, in a market where 39.9 million people were living with HIV in 2023 and 1.3 million new infections were recorded.

• Partners: NIAID, CAPRISA, ViiV
• Focus: treatment and prevention
• Market: 39.9M living with HIV

Halozyme’s manufacturing and quality control keep rHuPH20 products like Hylenex recombinant consistent, sterile, and safe, which is core to commercial supply. In 2025, Halozyme generated about $1.1 billion in revenue, so any batch failure would hit a meaningful base. Strong QA systems protect reliability and support repeat partner demand.

• rHuPH20 supply stays product-safe
• Quality systems reduce batch risk
• Reliable output supports 2025 revenue

Halozyme’s IP management protects patents around rHuPH20 and its delivery methods, which helps defend its ENHANZE platform from rivals and keeps royalty and licensing economics intact. In its latest filings, the Company said it supports a broad patent estate across key markets, and in 2024 it generated $1.02 billion in total revenue, with royalty revenue as a major driver.

• Protects rHuPH20 and delivery claims
• Supports royalty and licensing income
• Defends ENHANZE against competition

Halozyme’s scientific and regulatory expertise spans drug delivery, biologics, clinical development, and global filings, which lets partners add subcutaneous dosing to approved medicines with less execution risk. In 2024, Halozyme generated about $1.0 billion in revenue, showing how this know-how converts into commercial scale.

• Drug delivery and biologics know-how
• Clinical and regulatory execution
• Supports subcutaneous product upgrades

Halozyme’s global operating footprint spans 6 countries, including the United States, Switzerland, Ireland, Belgium, and Japan, which supports partner management, local execution, and faster commercialization across regions. That reach matters for a company that reported 2025 revenue of about "$1.0 billion" and depends on international collaboration to scale its enzyme-based platform.

• 6-country operating base
• Supports regional partner programs
• Helps commercialization outside the U.S.

Halozyme helps partners extend mature therapies by moving them into subcutaneous formats, which can refresh differentiation and keep products relevant longer. Its ENHANZE delivery tech has supported more than 30 partnered programs and, in 2025, helped drive annual revenue above $1 billion, showing how lifecycle extension can protect share and sustain partner value.

• New delivery format refreshes older brands
• Subcutaneous use supports longer product life
• Partners keep relevance and pricing power

Halozyme Therapeutics, Inc. uses a licensing and collaboration model, so partners can add subcutaneous delivery without building that tech in-house. In 2025, Halozyme generated more than $1 billion in revenue, with value shared through upfront milestones, royalties, and wider product adoption tied to ENHANZE.

• Lower partner R&D burden
• Milestones plus recurring royalties
• Scales through product adoption

Halozyme Therapeutics, Inc. mainly manages customer relationships through licensing, supply, and milestone contracts that spell out development roles, economics, and performance duties. This model supports recurring oversight, renewals, and partner management across a platform that has driven $1.0 billion-plus in annual revenue.

• Licensing sets partner rights.
• Supply terms define execution.
• Milestones link pay to progress.
• Renewals keep contracts active.

Halozyme supports partners with medical, regulatory, and launch coordination, which helps subcutaneous products move from approval to real use faster. This support matters because Halozyme reported 2024 revenue of $1.12 billion, and the company’s partner model depends on trust after approval and smooth field adoption.

• Medical, regulatory, and launch help
• Speeds real-world adoption
• Reinforces post-approval trust

Halozyme Therapeutics, Inc. uses partner-led filings and launches to move ENHANZE-based products across the U.S., Europe, and Japan, so one development package can support multi-market expansion. Its latest reported annual revenue topped $1 billion, showing this channel helps turn regional approvals into broad commercial scale.

• Partner files local approvals
• Launches across 3 key regions
• Supports faster market expansion

Halozyme uses scientific and conference events to show ENHANZE data to pharma and research audiences, which helps validate the platform and support partner talks. That visibility matters for business development: in 2024, Halozyme reported $1.0 billion in total revenue, showing how partner-led adoption can scale when the science is seen and trusted.

• Shows platform data to expert audiences

• Builds trust for new partnerships

• Supports Halozyme business development

Patients with chronic disease are the end users for Halozyme Therapeutics, Inc., especially in oncology, immunology, immunodeficiency, and rare disease care. The segment spans 4 core groups: CLL, lymphoma, MS, and immunodeficiency, and they value less invasive subcutaneous dosing instead of IV infusions.

• CLL and lymphoma
• MS and immunodeficiency
• Less invasive administration

Halozyme serves research and public health institutions like NIAID and CAPRISA, which fund HIV research, prevention, and trial work. NIAID’s FY2025 budget was about $6.6 billion, showing the scale of non-commercial platform demand for enzyme-based delivery and research tools.

• Non-commercial platform use

• HIV research and prevention focus

• Backed by large public funding

Halozyme Therapeutics, Inc.'s SG&A covers corporate admin, business development, and partner management, and it scales with a global licensing model that adds country-by-country overhead. It also funds commercialization support for partners, so this line stays tied to deal count, geography, and launch activity.

• Corporate admin and BD overhead
• Global footprint lifts costs
• Supports licensing and commercialization

Halozyme Therapeutics, Inc.’s 2025 cost structure is IP-heavy: patent prosecution, defense, and contract management are core expenses because the ENHANZE platform depends on strong patent protection to defend pricing and royalty economics. Legal spend also supports collaboration agreements with partners, which are central to how the business monetizes its technology.

• Patent defense protects platform value
• Contract work supports partner deals
• IP spend helps defend royalties

Hylenex recombinant is Halozyme Therapeutics, Inc. direct commercial product, used for subcutaneous fluid delivery, drug dispersion, and radiopaque agent resorption, so it adds product sales on top of licensing income. In 2025, Halozyme reported about $1.0 billion in total revenue, and Hylenex helps diversify cash flow beyond royalties.

• Direct product sales, not just licenses
• Supports subcutaneous delivery use cases
• Adds recurring revenue diversification

Halozyme Therapeutics, Inc. can earn supply and collaboration revenue from manufacturing support, bulk drug supply, and partner services inside broader alliance deals. In 2025, this stream stayed smaller than royalty income, but it still added cash flow to a business that has already generated more than $1 billion in annual revenue.

• Supports partner manufacturing
• Bundled in collaboration contracts
• Complements royalties and licenses